Status | Study |
Completed |
Study Name: Neural Basis of Language Processing Condition: Oligoastrocytoma Astrocytoma Oligode Date: 2016-09-13 Interventions: Device: fMRI Patient with grad |
Not yet recruiting |
Study Name: Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas Condition: Glioblastoma Oligodendroglioma Date: 2016-08-11 Interventions: Drug: RRx-001 dose escalation with TMZ + RT |
No longer available |
Study Name: Expanded Access to ANG1005 for Individual Patients Condition: Anaplastic Astrocytoma Anaplastic Oligodendroglioma Date: 2016-04-27 Interventions: Drug: ANG1005 |
Recruiting |
Study Name: First in Patient Study for PF-06840003 in Malignant Gliomas Condition: Oligodendroglioma Astrocytoma Date: 2016-04-27 Interventions: Drug: PF-06840003 Daily Oral PF-06840003 |
Recruiting |
Study Name: Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved Condition: Oligodendroglioma Oligoastrocytoma Date: 2015-08-18 Interventions: Drug: Palbociclib Palbociclib will be administered orally at a dose of 125 mg/day, until disease progres |
Recruiting |
Study Name: A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas Condition: Astrocytoma Oligodendroglioma Date: 2014-07-30 Interventions: Drug: Temozolomide 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles. |
Recruiting |
Study Name: Multicenter Safety Trial Assessing an Innovative Tumor Molecular and Cellular Print Medical Device in Glioma Condition: Glioma : Oligodendroglioma or Astrocytoma Date: 2013-10-10 Interventions: Device: Molecular and cellular tumor print Medical Device (ProTool) Proteomic, genomic and cellular cult |
Completed |
Study Name: Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Condition: Anaplastic Oligodendroglioma Anaplastic Oligoastrocytoma Date: 2013-04-29 Interventions: Drug: Temozolomide Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 2 |
Terminated |
Study Name: Treatment Strategy for Low-grade Gliomas Condition: Astrocytomas Oligodendrogliomas Date: 2009-05-08 Interventions: Radiation: Radiation therapy Drug: Temozol |
Completed |
Study Name: Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Condition: Anaplastic Astrocytoma Oligodendroglioma Date: 2008-07-15 Interventions: Drug: Temozolomide 200 mg/m2 b |